Michael Tillery, PA
Medical · Greensboro, NCNPI 1558725580
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Cvrx, Inc. accounts for 75.1% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $12,324 and has fallen 87.7% since, to $1,518 in 2025. Among medical clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $100.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$15K
- Impulse Dynamics (USA) Inc.$1K
- Medtronic$1K
- Novartis$475
- Amgen$257
- Boehringer Ingelheim$167
- plus $1K from 23 others
What the payments were for
- Consulting fees$11,17558%
- Travel & lodging$3,59118%
- Food & beverage$4,65424%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 44 | $14,585 |
| Impulse Dynamics (USA) Inc. | 14 | $1,428 |
| Medtronic | 10 | $1,270 |
| Novartis | 36 | $475 |
| Amgen | 17 | $257 |
| Boehringer Ingelheim | 12 | $167 |
| Abbott | 6 | $145 |
| Biotronik Inc. | 1 | $139 |
| Boston Scientific | 5 | $130 |
| Biosense Webster, Inc. | 1 | $99 |
| E.r. Squibb & Sons, L.L.C. | 7 | $90 |
| Johnson & Johnson | 6 | $82 |
| Bayer | 4 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Irhythm Technologies, Inc. | 3 | $53 |
| AstraZeneca | 4 | $53 |
| Scpharmaceuticals Inc. | 2 | $48 |
| Philips North America LLC | 2 | $36 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Merck | 2 | $30 |
| Novo Nordisk | 2 | $27 |
| Edwards Lifesciences | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$14,054
- OPTIMIZER$1,968
- LINQ II$941
- Acticor 7 VR-T DX$139
- Reveal LINQ$134
How this compares
$19,420 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 148 | $152,948 |
| EntrestoSacubitril/Valsartan | 30 | $40,915 |
| XareltoRivaroxaban | 19 | $20,190 |
| Dofetilide | 54 | $6,874 |
| Metoprolol Succinate | 213 | $3,574 |
| Flecainide Acetate | 64 | $2,954 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 53 | $1,844 |
| Amiodarone Hcl | 146 | $1,746 |
| Carvedilol | 77 | $957 |
| Colchicine | 69 | $577 |
| Potassium Chloride | 49 | $567 |
| SotalolSotalol Hcl | 14 | $540 |
| Furosemide | 71 | $359 |
| Bisoprolol Fumarate | 12 | $329 |
| Losartan Potassium | 53 | $318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $475 | $40,91530 claims |
| Johnson & JohnsonXarelto | $82 | $20,19019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.
Other medical in Greensboro
- David TysingerGreensboro$10K
- Brittainy SimmonsGreensboro$10K
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$265K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.